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Aim: To assess the evolution of occupational asthma (OA) depending on whether the patient
avoids or continues with exposure to the offending agent.
Methods: Study in patients diagnosed with OA using a specific inhalation challenge. Patients
underwent the following examinations on the same day: clinical interview, physical examina-
tion, forced spirometry, methacholine test and determination of total IgE. Clinical improve-
ment, deterioration or no change were defined according to the changes seen on the GINA
severity scale at the time of diagnosis.
Results: Of the 73 patients finally included, 55 had totally ended exposure and 18 continued to
be exposed at work. Clinical improvement was observed in 47% of those who had terminated
exposure and in 22% of those who remained exposed; clinical deterioration was observed in
14% and 17% respectively (p Z 0.805). Logistical regression analysis, including the type of
agent and the persistence or avoidance of exposure among the variables, did not show any pre-
dictive factors of clinical evolution. Similarly, the changes in FEV1 and in bronchial hyperre-
sponsiveness were not associated with the avoidance or continuation of exposure to the
causative agent.eumologia, Hospital General Vall d’Hebron, Passeig Vall d’Hebron, 119, 08035 Barcelona, Spain. Tel.:
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1364 X. Munoz et al.Conclusions: Avoiding exposure to the causative agent in patients with OA does not seem to
improve prognosis in this disease. Despite these findings, there is insufficient evidence to
recommend a change in current management guidelines.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Occupational asthma (OA) is the most frequent work-
related respiratory disease in developed countries [1,2]
and it is estimated that roughly 10% cases of bronchial
asthma and between 15 and 25% of adult onset asthma may
be of occupational origin [3,4].
For workers with OA caused by a respiratory sensitizer,
complete and definitive removal from exposure to the
sensitizing agent has usually been recommended as the
most efficient therapeutic approach [5e9]. However,
bearing in mind that cessation of exposure is often not
feasible [10], in recent years a number of meta-analyses
have been carried out to compare the effects of these
two management options [11e14]. The results of these
systematic reviews indicate that the available data on the
prognosis of OA are insufficient to enable physicians to
provide confident, informed advice to patients with the
disease.
Probably this conclusion is reached because the majority
of the more than 100 papers published so far are hetero-
geneous single-center studies, with small patient samples
and based on a single causative agent; all apply an obser-
vational approach and, for ethical reasons, none have
randomized patients to avoid or continue exposure to the
causative agent [15,16].
The aim of the present study is to assess the evolution of
all patients diagnosed with OA in the last ten years at two
centers in our country according to the persistence or
cessation of exposure to the causative agent and, on the
basis of the GINA classification, of asthma severity [17]. The
study design also allows an assessment of the influence on
the prognosis of OA of variables that have not been widely
studied to date, such as the medical treatment received
and the type of causative agent.Material and methods
Patients and design
This cross-sectional study was approved by the Ethics
Committee of the two participating centers. Using the da-
tabases from each center, all patients who had been diag-
nosed with immunological OA by specific inhalation
challenge (SIC) were selected. All patients included had at
least one year of follow-up since diagnosis. Between
September 2010 and June 2011, patients were scheduled
for a visit at the pulmonary function laboratory after having
discontinued treatment with inhaled corticosteroids and
long-acting beta2 agonists 24 h previously and the use of
short-acting beta2 agonists at least six hours previously. Allpatients provided written informed consent prior to
participation.
First, a careful review of clinical histories at the time of
diagnosis was carried out. The GINA classification that pa-
tients had at the time of diagnosis was made retrospectively
with data from the clinical history andwas basedprimarily on
the treatment that patients were receiving at this time.
Later, patients were interviewed again, placing special
emphasis on whether they had avoided exposure with the
causative agent, time between diagnosis and avoidance of
exposure and, in the case of persistence of exposure,
whether they worked with protection or not. They were also
asked about any medication they used. With this informa-
tion, the classification of asthma severity was established in
accordance with the new GINA guidelines [17]. Patients also
completed the asthma control questionnaire (ACQ) [18].
Spirometry and a methacholine challenge were then per-
formed. Finally, blood analysis was performed, and eosino-
phil count and total IgE were recorded.
Patientswere considered to present clinical improvement
or deterioration when a change in the GINA asthma severity
classification in either direction was observed. Improvement
or deterioration in bronchial hyperresponsiveness and/or the
degree of bronchial obstruction was recorded when changes
in the PC20 > 2 folds were observed or in FEV1 > 10% with
respect to the value at the time of diagnosis.
Atopy and smoking status
Patients were considered atopic if they had at least one
positive prick test to any common environmental allergen
[19]. Non-smokers were patients who had never smoked
and ex-smokers were those who had not smoked for at least
six months. The number of pack-years was calculated.
Spirometry and methacholine challenge
Spirometry was performed with a Datospir 200 (Sibel, Bar-
celona) instrument, following the European Respiratory So-
ciety (ERS) and American Thoracic Society (ATS) guidelines
[20]. The reference values used were those proposed for
the Mediterranean population [21]. Bronchial challenge with
methacholine was performed with the method described by
Chai et al. [22] (Online repository). The methacholine chal-
lenge was considered negative if the PC20 FEV1 was higher
than 16 mg/ml, in accordance with ATS guidelines [23].
Statistical analysis
Data are tabulated providing median and range of each
variable for quantitative variables and absolute frequencies
Figure 1 Number of patients who were screened and
completed the study.
Evolution of occupational asthma 1365(counts) for each category in qualitative variables. Differ-
ences between follow-up and baseline for each group were
tested using a non-parametric Wilcoxon rank test for
quantitative variables and a chi-square test for qualitative
variables. Logistic regression and Multiple Factor Analysis
[24,25] were used to analyse the effects of potential fac-
tors on the dependent variables (online repository). SPSS
11.0 for windows (SPSS, INC, Chicago, IL) and the open-
source statistical language R were used for the statistical
analysis. The level of statistical significance was set at
p < 0.05.Table 1 Baseline characteristics of individuals included and ex
Inclu
Age, yrs 42 (1
Sex, M/F 42/3
Smoking habit S/NS/ExS 15/4
Packs/year 15 (5
Time from exposure to diagnosis, months 180 (
Time from symptom onset to diagnosis, months 47 (1
Time from diagnosis to avoidance, months 2.5 (
Agent, LMW/HMW 50/2
Atopy, yes/no (% yes) 31/3
Rhinitis, yes/no (%yes) 53/2
Conjunctivitis, yes/no (% yes) 33/4
Dermatitis, yes/no, (% yes) 19/5
Total IgE, kU/L 115 (
% Blood eosinophils 4.7 (
FEV1, % predicted 92 (5
FVC, % predicted 94.5
FEV1/FVC, % 78 (5
Methacholine, % þ 78%
PC20, mg/ml 1.8 (
SIC response
(E/L/D/O)
23/2
% Fall SIC 25 (1
GINA
NA/I/MiP/ModP/SP
0/23
% 0/3
LMW e low molecular weight; HMW e high molecular weight; SIC e sp
e mild persistent; ModP e moderate persistent; , SP e severe persist
*p Z 0.805.Results
Between 2000 and 2009, 178 patients at the two centers
were diagnosed with OA with a positive SIC. One hundred
and five patients were excluded from the study because
contact was lost or they refused to participate (Fig. 1).
Table 1 compares the baseline characteristics of the pa-
tients finally included and those excluded and Table 2
compares the baseline characteristics and the results ob-
tained in the follow-up between exposed and non-exposed
patients.
Analysing patients according to exposure to high or low
molecular weight agents, changes were only observed in
the variables related to atopy. Patients who avoided con-
tact with high molecular weight agents improved their
symptoms of rhinitis, conjunctivitis and the percentage of
eosinophils in blood (p Z 0.002, 0.004, 0.018, respec-
tively), while in those who remained exposed the symptoms
of rhinitis and conjunctivitis deteriorated (p Z 0.039 and
0.012, respectively) although the percentage of eosinophils
in blood also fell (p Z 0.003). These changes, with the
exception of an improvement in rhinitis in the patients who
avoided contact (pZ 0.020), were not observed in patients
exposed to low molecular weight agents (Table 1 online
repository).
Comparing the characteristics at the time of diagnosis of
individuals who presented clinical improvement (n Z 30)
with those who remained unchanged (nZ 32) or those who
deteriorated (n Z 11) patients who improved showed a
higher degree of severity on the GINA classification,cluded from the study.
ded n Z 73 Excluded n Z 105 p
8e65) 38 (22e60) 0.258
1 60/45 0.541
8/10 28/61/16 0.563
e60) 15.5 (2e60) 0.967
6e710) 127 (4e607) 0.192
e430) 36 (1e430) 0.216
0e224) e e
3 75/30 0.398
1 (50%) 51/45 (53%) 0.495
0 (73%) 71/34 (68%) 0.294
0 (45%) 52/53 (49%) 0.339
4 (26%) 31/74 (29%) 0.368
5e2393) 103.5 (8e2509) 0.706
0e29.9) 4.4 (0e25) 0.095
2e131) 93 (46e126) 0.702
(49e148) 94 (52e131) 0.999
0e99.2) 80.5 (52e98) 0.039
79% 0.533
0.06e16) 1.4 (0.06e16) 0.075
9/16/5 24/46/12/13 0.358
2e50) 23 (14e50) 0.072
/11/25/14
1/15/35/19
0/25/37/36/7
% 0/24/35/34/7
0.004
ecific inhalation challenge; NA e no asthma; I e intermittent; MiP
ent; E early; L e late; D e dual; O e others.
Table 2 Baseline and follow-up characteristics of patients finally included (divided according to exposure/non-exposure to
the causative agent).
Non-exposed n Z 55 Exposed n Z 18
Baseline Follow-up p Baseline Follow-up p
Age, yrs 41 (18e65) e e 44 (25e57) e e
Sex, M/F 35/20 e e 7/11 e e
Smoking habit
S/NS/ExS
11/36/8 4/12/2
Pack/year 15 (5e60) 14.5 (7e21)
Time from exposure to diagnosis,
months
120 (6e710) e e 242 (12e539) e e
Time from symptom onset to
diagnosis, months
48 (2e377) e e 41 (1e430) e e
Time from diagnosis to avoidance,
months
e 1.5 (0e224) e e 30 (6e120) e
Agent, LMW/HMW 38/17 e e 12/6 e e
Atopy, yes/no (% yes) 23/21 (52%) e e 8/10 (44%) e e
Rhinitis, yes/no (% yes) 39/16 (71%) 22/32 (41%) 0.001 14/4 (78%) 14/4 (78%) 0.182
Conjunctivitis, yes/no (% yes) 25/30 (45%) 13/41 (24%) 0.027 8/10 (44%) 9/9 (50%) 0.149
Dermatitis, yes/no (% yes) 13/42 (31%) 6/48 (11%) 0.065 6/12 (33%) 4/14 (22%) 0.125
Total IgE; kU/L 118 (5e2393) 101 (5.9e1611) 0.858 75 (10e696) 105.5 (18e1212) 0.362
% Blood eosinophils 4.5 (0e29.9) 3.0 (0.9e29.2) 0.006 5 (0e25) 2.6 (0.8e4.8) 0.028
FEV1; % predicted 93 (60e130) 90 (52e131) 0.072 89.5 (64e113) 93 (60e131) 0.554
FVC; % predicted 95.5 (71e148) 91.5 (49e138) 0.011 93 (74e123) 90 (70e120) 0.434
FEV1/FVC% 78 (58e99.2) 77 (50e97) 0.150 76 (52e92) 78.3 (58.4e89.7) 0.777
Methacholine, % þ 89% 78% 0.0001 67% 51% 0.006
PC20, mg/ml 2 (0.06e16) 1.6 (0.06e16) 0.780 1.2 (0.13e8) 1.3 (0.4e8.5) 0.925
Response to SIC (E/L/D/O) 17/24/12/2 e e 6/5/4/3 e e
% fall SIC 25 (12e50) e e 22 (8e41) e e
GINA
NA/I/MiP/ModP/SP
0/16/6/20/13 1/30/6/8/10 0.001 0/7/5/5/1 0/8/4/4/2 0.861
Better/worse/same* e 26/8/21
47%/14%/38%
e 4/3/11
22%/17%/61%
ACQ: Control/Parcial Control/no control** e 34/14/7
62%/25%/13%
e 13/2/3
72%/15%/23%
LMW e low molecular weight; HMW e high molecular weight; SIC e specific inhalation challenge; NA e no asthma; , I e intermittent; MiP
e mild persistent; ModP e moderate persistent; , SP e severe persistent; E early; L e late; D e dual; O e others.
*p Z 0.805 **p Z 0.437.
1366 X. Munoz et al.although they had higher FEV1 and better FVC than those
who deteriorated (Table 3). No significant differences were
observed in the univariate analysis in the rest of the vari-
ables analysed.
Performing a logistical regression analysis considering
the changes in the GINA classification as independent var-
iable and comparing subjects who improved with those who
remained stable or deteriorated, no predictors of these
changes in the GINA classification were found (Table 2
online supplement). Only one model which included
avoidance of the agent, better FEV1 and better FEV1/FVC%
quotient/ratio presented a sensitivity of 77% and a speci-
ficity of 65%, although the differences were not significant
(Fig. 2, Table 3 online supplement). In the same analysis,
considering the changes in FEV1 or in PC20 as independent
variables, no predictors of the effect were found (Table 2
online repository).
Performing a new logistic regression analysis, also
considering the changes in the GINA classification as inde-
pendentvariablebutcomparing the individualswho improvedor remained stable with those who deteriorated, again no
variables predicting the effect were found (Table 4 online
repository). Only one model, which in this case included
timeelapsed between symptomonset anddiagnosis, a poorer
FEV1, FVCandFEV1/FVC%,presenteda sensitivityof 84%anda
specificity of 36%, although again the differences were not
significant (Fig. 3, Table 5 online repository). Interestingly,
neitheravoidanceof thecausativeagentnor the typeofagent
was associated with worse prognosis.
Multiple Factor Analysis showed that with three com-
ponents the percentage of variability explained was 36.8%.
However, when four variables were removed a rate of 50%
was obtained with the three first components, the results
being very similar. Representing the subjects in the three
main axes in three dimensions, no groupings were formed
related to the type of causative agent and continuation or
cessation of the exposure. The first axis of the graph is
related to improvement or deterioration, and so the chart
suggests that avoiding exposure is not related to improve-
ment or deterioration (Fig. 4).
Table 3 Baseline characteristics of patients who presented clinical improvement, deterioration, or no change on the basis of
the GINA classification during follow-up.
Improved n Z 30 Worse n Z 11 No change n Z 32 Improved
vs worse
Improved
vs no change
Worse
vs no change
Age, yrs 40.5 (21e65) 42.0 (37e55) 42.0 (18e57) 0.591 0.927 0.651
Sex, M/F 17/13 7/4 18/14 0.688 0.242 0.668
Smoking habit
S/NS/ExS
10/18/2 2/6/3 3/24/5 0.176 0.059 0.442
Pack/year 11 (5e30) 20 (12e21) 17.5 (5e60) 0.222 0.195 0.909
Time from exposure to
diagnosis, months
150 (6e710) 173 (18e529) 189 (12e589) 0.873 0.933 0.924
Time from symptom onset
to diagnosis. months
48 (3e377) 77 (10e430) 42 (1e334) 0.612 0.348 0.209
Time from diagnosis to
avoidance, months
11/19 3/8 9/23 0.574 0.525 0.957
Agent, LMW/HMW 14/14 2/5 16/11 0.309 0.366 0.141
Atopy, yes/no 23/7 7/4 23/9 0.404 0.613 0.608
Rhinitis, yes/no 14/16 4/7 15/17 0.556 0.893 0.545
Conjunctivitis, yes/no 7/23 2/9 10/22 0.724 0.437 0.405
Dermatitis, yes/no 105 (5e2393) 244 (23e443) 115 (7e1388) 0.643 0.901 0.414
Total IgE, kU/L 4.6 (2e29.9) 8 (4e15.4) 4.7 (0e25) 0.138 0.519 0.208
% Blood eosinophils 93 (71e119) 88 (64e100) 92.5 (60e130) 0.033 0.172 0.328
FEV1, % predicted 100 (75e129) 91 (72e104) 93 (71e148) 0.015 0.022 0.555
FVC, % predicted 78 (58e90) 75 (62e87) 78.5 (52e992) 0.530 0.129 0.110
FEV1/FVC, % 75 91 77 0.809 0.648 0.328
PC20, mg/ml 1.89 (0.06e16) 1.77 (0.25e16) 2.2 (0.13e16) 0.787 0.649 0.615
SIC response (E/L/D/O) 10/12/6/2 4/4/3/0 8/13/7/4 0.807 0.958 0.716
% Fall SIC 24.5 (12e50) 26.0 (17e50) 25.0 (8e50) 0.806 0.581 0.949
GINA
NA/I/MiP/ModP/SP
1/7/14/8 5/1/5/0 17/3/6/6 0.004 0.580 0.218
Avoidance of exposure:
yes/no (%yes)
26/4 (87%) 8/3 (73%) 21/11 (66%) 0.510 0.132 0.665
LMW e low molecular weight; HMW e high molecular weight; SIC e specific inhalation challenge; NA e no asthma; , I e intermittent; MiP
e mild persistent; ModP e moderate persistent; , SP e severe persistent; E early; L e late; D e dual; O e others.
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The most significant result of the present study is probably
the fact that avoiding exposure to the causative agent of
OA did not statistically significantly improve the prognosis
of these patients. The analyses performed show that
avoiding exposure does not lead to clinical improvement
and that the percentage of patients who deteriorate is in-
dependent both of the type of agent and of whether or not
the agent is avoided. Nor was termination or persistence of
exposure associated with any changes in the degree of
obstruction or bronchial hyperresponsiveness.
The majority of studies included in four recent meta-
analyses [11e14] focus on clinical aspects, and few studies
have centered on evaluating the degree of obstruction in
terms of the FEV1 or the degree of bronchial hyper-
responsiveness as determined by PC20 methacholine. To
our knowledge, few studies to date have analysed the de-
gree of bronchial inflammation assessed by the eosinophil
count in induced sputum in patients who either continued
or terminated exposure. In these studies, the cessation of
exposure showed a trend of improvement in sputum
eosinophilia [26,27].
In relation to the clinical aspects of OA, the systematic
review conducted by Rachiotis et al. [12], found thatcomplete symptomatic recovery varied from 0% to 100%
with a pooled prevalence of 32%. Similar results were re-
ported by Vandenplas et al. [28]. The present study is the
first to establish improvement or deterioration by deter-
mining the severity of the asthma according to the GINA
guidelines [17]. Although 44% of patients who avoided
exposure improved compared with only 22% of those who
remained exposed, the differences were not significant. In
fact, the patients who improved were the ones who pre-
sented poorer classifications on the GINA at the time of
diagnosis, regardless of whether or not they avoided
exposure.
Delay in diagnosis, the degree of intensity of the symp-
toms prior to diagnosis and patients’ age have been sug-
gested as prognostic factors [7,29e33] that determine the
persistence of asthma. In the present study, avoidance of
exposure to the causative agent and a lower degree of
bronchial obstruction may explain the improvement in
symptoms, although the associations were not significant.
When comparing the subjects who deteriorated with those
who remained stable or improved, longer delay in diagnosis
and above all the greater alteration in the spirometry pa-
rameters seemed to be associated with poor prognosis, but
no association was found between poor prognosis and the
type of agent or avoidance or continuation of exposure.
Figure 2 ROC curve considering GINA classification as inde-
pendent variable, comparing patients whose symptoms
improved versus those whose symptoms remained the same or
deteriorated.
Figure 3 ROC curve considering GINA severity classification
as independent variable, comparing patients whose symptoms
deteriorated versus those whose symptoms improved or
remained the same.
1368 X. Munoz et al.These results suggest that OA probably does not differ
greatly from non-occupational allergic asthma, since the
rate of patients who deteriorate is around 15% and is in-
dependent of the treatment administered and of the
avoidance or continuation of exposure. The percentage of
patients with difficult-to-control severe asthma in the
general population is around 10% [34].
Probably the overall improvement of OA should be
assessed not only in terms of the improvement of symptoms
but also of the degree of obstruction and the degree of
bronchial hyperresponsiveness. In the present study we did
not find a relation between any of the variables (once again
including the type of agent or the avoidance or continua-
tion of exposure) and a deterioration or improvement in
FEV1. Chang Yeung et al. [32], studying 185 workers
exposed to plicatic acid, found higher values for those who
terminated exposure. Paradoxically, Moscato et al. [4]
studying 25 patients exposed indistinctly to HMW or LMW
agents found better values for subjects who remained
exposed. In fact, there is little information available on
how rapidly lung function declines in those who continue to
be exposed, or how removal from exposure affects lung
function. Piirila et al. [35] reported a mean rate of decline
of 40 ml/year in 91 selected subjects with isocyanate-
induced OA, although 12 of these remained exposed to
the causative agent during the follow-up period. A recent
report focused only on patients who terminated exposure
observed that FEV1 declined rapidly in exposed workers andcontinued to decline, but at a slower rate, following
removal of exposure [16].
The situation is similar in the case of bronchial hyper-
responsiveness. The systematic review by Rachiotiis et al.
[12] found a pooled estimate of persistent hyper-
responsiveness of 73%. Patients whose disease had been
attributed to a LMW agent, and those from European work-
places were less likely to have persistent hyper-
responsiveness. De Groene et al.’s meta-analysis [14] found
differences depending on the criterion used to assess
bronchial hyperresponsiveness. Indeed, only two studies
out of the eight which analysed the standard mean differ-
ence in the follow-up showed an improvement in the de-
gree of bronchial hyperresponsiveness in patients who
avoided exposure [6,32]. However, the situation is more
confusing in the studies that analysed the changes obtained
by subtracting the PC20 values during follow-up from the
baseline values. In four studies [30,33,36,37] in which the
causative agent was LMW, an improvement was observed in
two [32,37]. In the present study, taking as significant a
two-fold change in the PC20 methacholine, no differences
were found in relation to the exposure or to the type of
causative agent; nor did we identify any factors that might
predict these changes.
In view of these results we performed a multiple factor
analysis, a descriptive multivariate statistical technique
useful to analyse several groups of variables defined in the
same samples [24,25]. In our study, the multiple factor
Figure 4 Multiple Factor Analysis. A: Representation of individuals according to type of agent in principal components 1, 2 and 3. B:
Representation of individuals according to whether or not they avoided contact with the agent in principal components 1, 2 and 3.
Evolution of occupational asthma 1369analysis confirms that avoiding exposure is not related to
improvement or deterioration of the disease.
This study has a number of limitations. First, the fact
that the severity of asthma was significantly lower in the
patients who were not included may have introduced a bias
in the results. The study does not account for the healthy
worker effect. The unavailability of the degree of asthma
control at the moment of diagnosis may be a source of
error; however, this factor would not have introduced bias,
because both the exposed and the non-exposed groups
received similar initial treatment. Information was avail-
able on the degree of asthma control in the follow-up
assessment. Very few patients were not controlled with the
ACQ [18], and there were no differences regarding avoid-
ance or persistence of exposure to the causative agent.
Other limitation of the present study is the relatively low
number of study subjects. However, we consider that the
results obtained are important enough to be highlighted in
a descriptive manner. Finally, another possible limitation
was the fact that the degree of improvement of the pa-
tients was not analysed: patients whose asthma symptoms
decreased from severe to intermittent or from severe to
moderate and vice versa were analysed in the same way.
Breaking down these multiple changes would have created
different groups and would have complicated the analysis.
In conclusion, our results do not seem to support the
recommendation that patients diagnosed with OA should
change their work place. Despite these findings, however,
there is insufficient evidence to recommend a change in
current management guidelines recommending adequate
avoidance of work place sensitizers, and especially chem-
icals, in workers with confirmed OA. Future well-designed
prospective studies to further address the efficacy of
environmental interventions in treating occupational
asthma are required to confirm these findings. In the
meantime, the best option seems to be to individualize the
treatment strategy according to the patient.Authors contributions
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